COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN

被引：1
|
作者：
Shibahara, H. [1 ]
Shiroiwa, T. [2 ]
Nakamura, K. [1 ]
Shimozuma, K. [1 ]
机构：
[1] Ritsumeikan Univ, Kusatsu, Japan
[2] Natl Inst Publ Hlth, Saitama, Japan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.532
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A415 / A416
页数：2
相关论文
共 50 条
  • [21] Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.
    Maruzzo, Marco
    Basso, Umberto
    Diminutto, Alberto
    De Giorgi, Ugo
    Fratino, Lucia
    Lo Re, Giovanni
    D'Angelo, Alessandro
    Donini, Maddalena
    Verderame, Francesco
    Ratta, Raffaele
    Procopio, Giuseppe
    Campadelli, Enrico
    Massari, Francesco
    Gasparro, Donatello
    Macrini, Sveva
    Messina, Caterina
    Giordano, Monica
    Maines, Francesca
    Zagonel, Vittorina
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [22] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [23] Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Sternberg, C. N.
    Molina, A.
    North, S.
    Mainwaring, P.
    Fizazi, K.
    Hao, Y.
    Rothman, M.
    Gagnon, D. D.
    Kheoh, T.
    Haqq, C. M.
    Cleeland, C.
    de Bono, J. S.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1017 - 1025
  • [24] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [25] COST EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL USING DATA FROM REAL LIFE TREATMENT PRAXIS IN SWEDEN
    Persson, U.
    Nilsson, S.
    Prutz, C.
    Hjortsberg, C.
    VALUE IN HEALTH, 2013, 16 (03) : A134 - A135
  • [26] ECONOMIC EVALUATION OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL IN SWEDEN
    Persson, U.
    Nilsson, S.
    Hjortsberg, C.
    Prutz, C.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [27] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [28] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
  • [29] Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
    Zhong, Lixian
    Pon, Vickie
    Srinivas, Sandy
    Nguyen, Nicole
    Frear, Meghan
    Kwon, Sherry
    Gong, Cynthia
    Malmstrom, Robert
    Wilson, Leslie
    PLOS ONE, 2013, 8 (05):
  • [30] Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
    ten Ham, Renske M. T.
    van Nuland, Merel
    Vreman, Rick A.
    de Graaf, Laurens G.
    Rosing, Hilde
    Bergman, Andre M.
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    Hovels, Anke M.
    VALUE IN HEALTH, 2021, 24 (01) : 121 - 128
12345